المؤلفون: Cejalvo, María J, Legarda, Mario, Abella, Eugenia, Cabezudo, Elena, Encinas, Cristina, García-Feria, Ana, Gironella, Mercedes, Iñigo, Belén, Martín, Jesús, Ribas, Paz, Ruíz, Mª Ángeles, González, Yolanda, Vicuña, Isabel, Ramírez, Ángel, Fernández, Pascual, de la Rubia, Javier

مصطلحات موضوعية: daratumumab, dialysis, multiple myeloma, relapse, Aged, Antibodies, Monoclonal, Disease-Free Survival, Female, Humans, Male, Middle Aged, Recurrence, Renal Dialysis, Retrospective Studies, Survival Rate

العلاقة: http://hdl.handle.net/10668/14782Test

الإتاحة: https://doi.org/10.1111/bjh.16286Test
http://hdl.handle.net/10668/14782Test

المؤلفون: de la Rubia, Javier^1,2 (AUTHOR) delarubia_jav@gva.es, Alonso, Rafael³ (AUTHOR), Clavero, María Esther⁴ (AUTHOR), Askari, Elham⁵ (AUTHOR), García, Alfonso⁶ (AUTHOR), Antón, Cristina⁷ (AUTHOR), Fernández, Margarita⁸ (AUTHOR), Escalante, Fernando⁹ (AUTHOR), García, Ana¹⁰ (AUTHOR), Rios-Tamayo, Rafael¹¹ (AUTHOR), Conesa, Venancio¹² (AUTHOR), Bermúdez, María Arancha¹³ (AUTHOR), Merchán, Beatriz¹⁴ (AUTHOR), Velasco, Alberto E.¹⁵ (AUTHOR), Blanchard, María Jesús¹⁶ (AUTHOR), Sampol, Antonia¹⁷ (AUTHOR), Gainza, Eukene¹⁸ (AUTHOR), Hernández, Prisma Montserrat¹⁹ (AUTHOR), Alegre, Adrián²⁰ (AUTHOR)

المصدر: Cancers. Jun2023, Vol. 15 Issue 11, p2964. 13p.

مصطلحات موضوعية: *THERAPEUTIC use of immunoglobulins, *RESEARCH, *SCIENTIFIC observation, *CONFIDENCE intervals, *IMMUNOGLOBULINS, *OPTIC nerve diseases, *CANCER relapse, *INVESTIGATIONAL drugs, *CELL receptors, *RETROSPECTIVE studies, *ACQUISITION of data, *TREATMENT effectiveness, *COMPARATIVE studies, *MEDICAL records, *DESCRIPTIVE statistics, *MULTIPLE myeloma, *PROGRESSION-free survival, *PATIENT safety, *OVERALL survival, *DISEASE risk factors

مصطلحات جغرافية: SPAIN

مستخلص: Simple Summary: Patients with multiple myeloma (MM) who become refractory to three or more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them, drugs directed against the BCMA antigen expressed in plasma cells are very appealing. Belantamab-mafodotin (belamaf) is the first antibody-drug conjugate against BCMA ready for clinical use. In this paper, we report the Spanish experience of belamaf monotherapy in 156 patients with RRMM. The overall response rate was 41.8%, with 39.8% of patients achieving a partial response or better. Median progression-free survival was 3.61 months, but interestingly, it increased to 14.47 months in patients achieving a minimal response or better. Treatment was well tolerated, ocular events being the most reported toxicity (87.9%; grade ≥ 3, 33.7%), but only two patients discontinued treatment due to side effects. Overall, our results confirm the safety and efficacy of belamaf in this poor prognosis subset of patients. Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, and multicenter study aimed to assess the efficacy and safety of single-agent belamaf in 156 Spanish patients with RRMM. The median number of prior therapy lines was 5 (range, 1–10), and 88% of patients were triple-class refractory. Median follow-up was 10.9 months (range, 1–28.6). The overall response rate was 41.8% (≥CR 13.5%, VGPR 9%, PR 17.3%, MR 2%). The median progression-free survival was 3.61 months (95% CI, 2.1–5.1) and 14.47 months (95% CI, 7.91–21.04) in patients achieving at least MR (p < 0.001). Median overall survival in the entire cohort and in patients with MR or better was 11.05 months (95% CI, 8.7–13.3) and 23.35 (NA-NA) months, respectively (p < 0.001). Corneal events (87.9%; grade ≥ 3, 33.7%) were the most commonly adverse events, while thrombocytopenia and infections occurred in 15.4% and 15% of patients, respectively. Two (1.3%) patients discontinued treatment permanently due to ocular toxicity. Belamaf showed a noticeably anti-myeloma activity in this real-life series of patients, particularly among those achieving MR or better. The safety profile was manageable and consistent with prior studies. [ABSTRACT FROM AUTHOR]

المؤلفون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano, Carlos, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

المساهمون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Lui, Sanz, Miguel Ángel, Solano, Carlo, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

مصطلحات موضوعية: Adult, Cyclophosphamide, Humans, Mycophenolic Acid, Retrospective Studies, Sirolimus, Transplantation Conditioning, Unrelated Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute

الوصف: Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35680995; info:eu-repo/semantics/altIdentifier/wos/WOS:000808391500001; volume:57; issue:9; firstpage:1389; lastpage:1398; numberofpages:10; journal:BONE MARROW TRANSPLANTATION; http://hdl.handle.net/20.500.11768/132811Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131605087

الإتاحة: https://doi.org/20.500.11768/132811Test
https://doi.org/10.1038/s41409-022-01725-3Test
https://hdl.handle.net/20.500.11768/132811Test

المؤلفون: Solana-Altabella, Antonio, Megías-Vericat, Juan Eduardo, Ballesta-López, Octavio, Boluda, Blanca, Cano, Isabel, Acuña-Cruz, Evelyn, Rodríguez-Veiga, Rebeca, Torres-Miñana, Laura, Sargas, Claudia, Sanz, Miguel Á., Borrell-García, Carmela, López-Briz, Eduardo, Poveda-Andrés, José Luis, De la Rubia, Javier, Montesinos, Pau, Martínez-Cuadrón, David

المصدر: Cancers; Apr2022, Vol. 14 Issue 8, p1921, 10p

مصطلحات موضوعية: CANCER chemotherapy, RETROSPECTIVE studies, ACQUISITION of data, MEDICAL care costs, MEDICAL care use, CANCER patients, HEALTH insurance reimbursement, MEDICAL records, HOSPITAL care, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation

مصطلحات جغرافية: SPAIN

مستخلص: Simple Summary: Studies addressing the economic costs and burden of secondary acute myeloid leukemia (sAML) are scarce in the literature. We analyzed this topic in a real-life population of sAML patients between 60–75 years receiving intensive chemotherapy induction. In elderly patients with sAML and intensive regimens, it entails an increase in costs and a longer hospital stay. In these specific patients, almost a third of the time is spent hospitalized after the diagnosis of sAML. There are no studies with this type of population and diagnosis, which gives added value to the results obtained. Pharmacoeconomic studies in patients with AML are being carried out due to the need to evaluate the cost-effectiveness of new oral drugs, therapeutic schemes with higher costs than previous treatments. Background: Information regarding the impact on healthcare systems of secondary acute myeloid leukemia (sAML) is scarce. Methods: A retrospective review of medical charts identified patients aged 60–75 years with sAML between 2010 and 2019. Patient information was collected from diagnosis to death or last follow-up. Outpatient resource use, reimbursement, frequency and duration of hospitalization, and transfusion burden were assessed. Forty-six patients with a median age of 64 years were included. Anthracycline plus cytarabine regimens were the most common induction treatment (39 patients, 85%). The ratio of the total days hospitalized between the total follow-up was 29%, with a sum of 204 hospitalizations (average four/patient; average duration 21 days). The total average reimbursement was EUR 90,008 per patient, with the majority (EUR 77,827) related to hospital admissions (EUR 17,403/hospitalization). Most hospitalizations (163, mean 22 days) occurred in the period before the first allogeneic hematopoietic stem cell transplant (alloHSCT), costing EUR 59,698 per patient and EUR 15,857 per hospitalization. The period after alloHSCT (in only 10 patients) had 41 hospitalizations (mean 21 days), and a mean reimbursement cost of EUR 99,542 per patient and EUR 24,278 per hospitalization. In conclusion, there is a high consumption of economic and healthcare resources in elderly patients with sAML receiving active treatments in Spain. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Puig, Noemí, de la Rubia, Javier, Jarque, Isidro, Salavert, Miguel, Montesinos, Pau, Sanz, Jaime, Martín, Guillermo, Sanz, Guillermo, Cantero, Susana, Lorenzo, Ignacio, Sanz, Miguel A

المصدر: International Journal of Hematology; Aug2007, Vol. 86 Issue 2, p186-192, 7p

مصطلحات موضوعية: ANTI-infective agents, ANTINEOPLASTIC agents, AUTOGRAFTS, BACTEREMIA, FEVER, HEMATOPOIETIC stem cell transplantation, OPPORTUNISTIC infections, PREANESTHETIC medication, DISEASE incidence, RETROSPECTIVE studies

مستخلص: Infectious complications are a major cause of morbidity and mortality in patients who undergo autologous stem cell transplantation (ASCT). We examined 476 patients with hematologic malignancies (401) or solid tumors (75) who underwent ASCT between February 1990 and May 2005. Anti-infectious prophylaxis consisted of different combinations of ciprofloxacin, cotrimoxazole, fluconazole, aerosolized amphotericin B, acyclovir, and intravenous immunoglobulins. Overall, 454 patients (95%) developed fever in the first 60 days after ASCT. In the majority of patients, initial antibiotic therapy consisted of broad-spectrum beta-lactamic with or without amikacin. A glycopeptide was administered as initial therapy in 86 cases. Overall, there were 132 (29%) clinically documented infections (37 pneumonias), 79 (17%) microbiologically documented infections (65 bacteremias), and 243 (54%) fevers of unknown origin. Coagulase-negative staphylococci (18, 25%) and E coli (18, 25%) were the organisms most frequently isolated. The pattern of infection did not change throughout the study except for a significantly higher incidence of bacteremia due to gram-positive bacteria in the first 5 years of the study. Infection-related mortality was 5% (21 cases), with pneumonia the most frequent cause of death. ASCT should be considered a low-risk procedure, although new therapeutic approaches for patients developing severe respiratory infections are still needed. [ABSTRACT FROM AUTHOR]

: Copyright of International Journal of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)